ThePMD

PSKW

PSKW is the innovation driver in biopharma loyalty marketing. We develop, execute, and manage (1) co-pay assistance initiatives using an array of tangible and virtual distribution channels, and (2) digital relationship tools that enhance physician/patient dialogue and help drive compliance and adherence. Co-Pay Assistance Initiatives: PSKW created the co-pay assistance industry and ...
 

PDQ Communications, Inc.

PDQ Communications is a healthcare communications company, assisting pharmaceutical manufacturers and others to update healthcare professionals with product information in a timely manner. PDQ MAIL aids the pharmaceutical manufacturer by delivering their message to healthcare providers in all practice settings. Custom mailings feature FLASH branding and are targeted to the ...
 

DMD

DMD is a national leader in connecting healthcare markets through comprehensive target-audience deployment services. DMD provides unique direct communication solutions to clients in the medical publishing, pharmaceutical marketing, medical advertising, health delivery system, and allied health sectors. With innovative technology and numerous consultative services, DMD enables its clients to create ...
 

Subscribe today

 

Over 25,000 healthcare contacts at your fingertips

Get full online access and a copy of The PMD in print.Contact Susan at 561-665-6024 or Click for more information »

PMD ReFresh

High Climber

Alan Mateo, EVP, global sales, Veeva Systems
 

Workspace

Ed Shankman, SVP, CCO, Natrel
 

More from ReFresh

Click here to sign up for the latest ReFresh, PMD's monthly newsletter update

Latest from MM&M

Merck will evaluate Keytruda cancer combo therapy

Merck will collaborate with Syndax to evaluate the pairing of an anti-PD-1 therapy in Keytruda with HDAC inhibitor entinostat.
 

Bayer expands MIT/Harvard collaboration

The focus will now include cardiovascular disease.
 

Five things for pharma marketers to know: Tuesday, March 31

Pfizer spent over $1 billion on ads last year; Monday's M&A activity accounted for about 25% of this year's total; Actavis is selling its Australian generics business